This synthetic lethal interaction forms the basis for the clinical efficacy of PARPi, which are used for the treatment of metastatic castration-resistant PCa in patients with mutations in BRCA1 and BRCA2. This evidence concerns the gene BRCA2 and posterior cortical atrophy.